Patent: 10,092,645
✉ Email this page to a colleague
Summary for Patent: 10,092,645
Title: | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
Abstract: | This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later. |
Inventor(s): | Stewart; Ross (Cambridge, GB), Morrow; Michelle (Cambridge, GB), Wilkinson; Robert (Cambridge, GB), Poon; Edmund (Cambridge, GB), Dovedi; Simon (Manchester, GB), Illidge; Tim (Manchester, GB) |
Assignee: | MedImmune Limited (Cambridge, GB) |
Application Number: | 14/740,876 |
Patent Claims: | see list of patent claims |
Details for Patent 10,092,645
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2034-06-17 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2034-06-17 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2034-06-17 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2034-06-17 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2034-06-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |